SonarMed operates in the healthcare technology sector, focusing on neonatal intensive care units (NICUs). The company offers the AirWave system, an FDA-cleared airway monitoring solution that provides continuous, real-time monitoring of endotracheal tube (ETT) movement, position, and obstruction. This technology aims to reduce complications associated with ETTs, such as unplanned extubations, which can lead to serious harm or even death in neonates.

SonarMed primarily serves hospitals and healthcare providers specializing in neonatal care. The company's business model revolves around selling the AirWave system and related services to these institutions. Revenue is generated through the sale of the monitoring devices, software subscriptions, and ongoing support services.

The market for SonarMed's products includes NICUs in hospitals globally, with a particular focus on regions with advanced healthcare systems. By addressing a critical need for improved patient safety and reducing unreimbursed hospital costs associated with ETT complications, SonarMed positions itself as a vital player in neonatal care.

Keywords: neonatal, ICU, endotracheal tube, real-time monitoring, FDA-cleared, patient safety, healthcare technology, AirWave system, unplanned extubation, hospital costs.